Trial Profile
Phase II pilot study of bortezomib (Velcade) and gemcitabine for patients with relapsed or refractory Hodgkin's lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 May 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Gemcitabine (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 17 Jul 2007 Status changed from recruiting to in progress.
- 16 Aug 2006 New trial record.